Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CHIKV hyperimmune immunoglobulins
- Development stage
- Phase 2
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Administration
- Intravenous, Intramuscular
01
Overview
Anti-CHIKV hyperimmune immunoglobulins are polyclonal antibody preparations derived from the plasma of individuals with high titers of antibodies against chikungunya virus (CHIKV). These preparations contain a broad spectrum of neutralizing antibodies targeting multiple epitopes on the CHIKV envelope proteins. The mechanism of action involves direct neutralization of the virus and engagement of Fc gamma receptors (FcγR) on immune cells, leading to enhanced Fc-effector functions such as antibody-dependent cellular cytotoxicity and phagocytosis. Preclinical studies have demonstrated that these immunoglobulins can reduce viral load and provide protection in animal models when administered post-exposure[1][4][8]. They are being investigated for both prophylactic and therapeutic use in chikungunya virus infection.
- Other names
- anti-chikungunya virus hyperimmune immunoglobulinsCHIKV-specific polyclonal IgGCHIKV immune globulin
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)CHIKV E2/E1 (Chikungunya virus envelope protein)
Beyond the preview
Go deeper on anti-CHIKV hyperimmune immunoglobulins.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CHIKV hyperimmune immunoglobulins.